Diagnostic Value of the CareTM HPV Test in Screening for Cervical Intraepithelial Neoplasia Grade 2 or Worse

about

Diagnostic Value of the CareTM HPV Test in Screening for Cervical Intraepithelial Neoplasia Grade 2 or Worse

Item

http://www.wikidata.org/entity/Q40238624

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Diagnostic Value of the CareTM ...... ial Neoplasia Grade 2 or Worse

@en

type

Item

label

Diagnostic Value of the CareTM ...... ial Neoplasia Grade 2 or Worse

@en

prefLabel

Diagnostic Value of the CareTM ...... ial Neoplasia Grade 2 or Worse

@en

P1476

Diagnostic Value of the CareTM ...... ial Neoplasia Grade 2 or Worse

@en

P2093

Afsarolsadat Tabatabaie

http://www.w3.org/2001/XMLSchema#string

Effat Heydari

http://www.w3.org/2001/XMLSchema#string

Mansour Moghimi

http://www.w3.org/2001/XMLSchema#string

Mojgan Karimi Zarchi

http://www.w3.org/2001/XMLSchema#string

Wesam Kooti

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India

Global cancer statistics, 2012

Optimal positive cutoff points for careHPV testing of clinician- and self-collected specimens in primary cervical cancer screening: an analysis from rural China

Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria

Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women.

Chapter 1: HPV in the etiology of human cancer.

Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.

Triage of HPV positive women in cervical cancer screening.

Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India

Cervical cancer screening following prophylactic human papillomavirus vaccination.

P304

687-693

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.22034/APJCP.2017.18.3.687

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28440976

http://www.w3.org/2001/XMLSchema#string

P932

5464485

http://www.w3.org/2001/XMLSchema#string